Targeting of Immune Response After Pneumococcal Vaccination

Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)

Inclusion Criteria:

• Males and females ≥ 18 and <65 years of age.
• General good health.
• Written informed consent.
• No previous vaccination against Pnc
• No previous history of Pnc pneumonia
• In pneumonia: Diagnosis of Pnc pneumonia within a week

Exclusion Criteria:

• < 18 years, ≥65 of age.
• In vaccinees: Acute disease at the time of enrollment.
• Pregnancy or lactation.
• Known immunodeficiency or immune suppressive treatment.
• Any chronic illness that might interfere with the immune response
• Alcohol or drug abuse
• Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).